The QualityStocks Daily Thursday, February 21st, 2019

Today's Top 3 StockMarketWatch

BUYINS.NET (IMDZ) +309.86%

StockMarketWatch (RGNP) +171.49%

QualityStocks (FTXP) +149.60%

The QualityStocks Daily Stock List

Northsight Capital, Inc. (NCAP)

Awesome Penny Stocks, OTC Markets, InvestorsHub, GuruFocus, Insider Monkey, Stockopedia, Equity Clock, Marketwired, The Street, Equities, MarketWatch, Barchart, WhaleWisdom, Stockhouse, Simply Wall St, and Uptick Newswire reported previously on Northsight Capital, Inc. (NCAP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northsight Capital, Inc. consists of a portfolio of online Cannabis-related websites that are undergoing development and operated by the Company. These sites incorporate numerous facets of the Cannabis industry. The Company is transitioning into two sectors. One is the Bitcoin ATM service industry. The other is its modern cannabis advertising and media platform. Northsight Capital is headquartered in Scottsdale, Arizona.

Northsight Capital does not sell or distribute any cannabis products. The Company is looking to acquire digital or publishing companies in the space. It has its 420Careers.com. This is a leading job site in the Cannabis space.   

Northsight Capital also has its WeedDepot.com. This website provides consumers with a geo-targeted map directory of medical and recreational dispensaries, head shops, doctors, attorneys and more within the Cannabis industry. Weed Depot has a whole platform of content suited for every aspect of advertising and marketing to consumers from all businesses in the cannabis industry.

Northsight Capital earlier acquired Crush Mobile, LLC. Crush Mobile has developed a group of dating sites with a presence in the Latino, Israeli, and African American communities. Crush Mobile is a part of the Company’s growing media group. Crush Mobile has incorporated into its dating applications suite Northsight Capital's "Joint Lovers" dating app that centers on the Cannabis space.

Northsight Capital reached an agreement in principal in 2018 to be the exclusive distributor of CBD products for SeniorsCBD, a brand of Seniors for CBD. Northsight Capital and Seniors for CBD signed an agreement in principal to create the first CBD product line specifically for the seniors’ market. Seniors for CBD (www.SeniorsforCBD.com) is a leader in the industry for educating and informing seniors on the continuing research on medical marijuana and CBD through bringing current news each day to their followers.

This past December, Northsight Capital announced that it launched its new enhanced cannabis careers web site, www.420Careers.com. This site first launched in 2010. It is considered one of the foremost career sites in the cannabis arena. The site has been updated with many new more user-friendly features. These features make it easier for job seekers to post their resumes and also makes it easier for employers to access them. The 420Careers site has 2,000 to 3,000 visitors a day and roughly 1 million-page views per month.

This month, Northsight Capital announced an agreement in principal to be the master distributer of 3 exclusive lines of CBD products. The initial orders will be shipped early next month. The lines include earlier announced SeniorsCBD, specializing in formulas specifically for seniors, LiquidMD, a CBD infused water, LiquidMD for pets, and Nature Grown CBD, Northsight’s generic brand.  

The Company is expecting to receive the initial shipment of its CBD products on or about the first week of March. First distribution will be through Northsight's broad online media presence and also independent sales and distribution outlets.

Northsight Capital, Inc. (NCAP), closed Thursday's trading session at $0.004, down 18.37%, on 1,070,820 volume with 36 trades. The average volume for the last 3 months is 453,988 and the stock's 52-week low/high is $0.0025/$0.0546.

chart

Petro River Oil Corp. (PTRC)

Market News Updates, Real Investment Advice, The Street, Corporate Information, Simply Wall St, Oil Voice, Wolf Street, OTC Stock Review, InvestorsHub, MarketWatch, Streetwise Reports, The Energy Report, Stockhouse, Wallet Investor, GuruFocus, Market Screener, Morningstar, 4-Traders, and YCharts reported earlier on Petro River Oil Corp. (PTRC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Petro River Oil Corp. utilizes 3D seismic technology to discover and develop oil and gas reserves in proven oil and gas basins. The Company’s core acreage is positioned in Osage County, Oklahoma. Petro River Oil owns a 14.52 percent equity interest in Horizon Energy Partners, LLC. Additionally, its President, Mr. Stephen Brunner, is a member of the Board of Managers of Horizon Energy Partners, LLC. An independent oil and gas exploration company, Petro River Oil is based in New York, New York. The Company also has an office in Kingwood, Texas.

Petro River Oil’s Management team has drilled more than 800-plus successful wells in the vicinity of the Company’s 87,754 acre Pearsonia West Lease Concession in Osage County, Oklahoma. Management’s historic success rate in the area is 90 percent.

Petro River Oil’s emphasis is on high rate return assets. The Company’s strategy is to apply modern technology, including 3D Seismic analysis, to exploit hydrocarbon-prone resources in historically prolific plays and underexplored prospective basins. This is to build reserves and to create value for Petro River Oil and its shareholders.

Petro River Oil has successfully drilled three additional wells and discovered two new oil fields in Osage County, Oklahoma since the end of April 2018. These are the North Blackland field and the Arsaga field. The success of the Company’s most recent exploration well, the Arsaga 25-2, was announced in July of 2018. Preliminary results indicated 30 feet of productive Mississippian Chat formation, with an estimated ultimate recovery of 50,655 barrels of oil equivalent based on the Reserve Report.

The Arsaga field is Petro River Oil’s largest oil field discovery with about 2,000 prospective acres and up to 100 well locations. With the success of the Arsaga field, and the West and North Blackland fields, the Company anticipates significant cash flow from oil and gas production this year.

At the end of July 2018, Petro River Oil announced its year end April 30, 2018 financials and 2018 guidance. Highlights include a 1,131 percent increase in oil and gas production in fiscal year 2018 from fiscal year ending April 30, 2017. Company production ramped up, with greater than 60 percent of the new production occurring in Q4.

Highlights also include a 395 percent increase in proved and probable reserves in fiscal year 2018  per the May 1, 2018 evaluation (Reserve Report) by independent engineering firm Cawley, Gillespie & Associates. Moreover, highlights include an 11.27 percent decrease in general and administrative expenses for fiscal year 2018.

Petro River Oil Corp. (PTRC), closed Thursday's trading session at $0.599, down 0.17%, on 1,015 volume with 2 trades. The average volume for the last 3 months is 14,194 and the stock's 52-week low/high is $0.3073/$1.75.

chart

Flexpoint Sensor Systems, Inc. (FLXT)

Tip Ranks, Business Insider, The Street, Stockhouse, Simply Wall St, Investopedia, Investing, Research and Markets, MarketWatch, Investors Hub, Uptick Newswire, Super Stock Screener, Equity Clock, Marketbeat, and Investor Place reported earlier on Flexpoint Sensor Systems, Inc. (FLXT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flexpoint Sensor Systems, Inc. is a technology company specializing in developing products that feature its patented Bend Sensor® and associated technology. The Bend Sensor's single-layer, thin film construction reduces expenses and mechanical bulk. It does so while introducing a range of functions and stylistic design possibilities that have never before been available in sensing technology. Flexpoint Sensor Systems is based in Draper, Utah and the Company lists on the OTC Markets.

The Company produces the Bend Sensor® for manifold applications, encompassing numerous markets. These markets include automotive and transportation, wearables, medical, industrial controls, consumer products, and toys/gaming. Flexpoint offers Consulting, Design, Development, and Manufacturing related to the adoption of the Bend Sensor® technology.

The Bend Sensor® product comprises a coated substrate, such as plastic, that changes in electrical conductivity as it is bent. Electronic systems connect to the sensor and measure with fine detail the amount of bending or movement that takes place. The single layer design of the Bend Sensor® eliminates many of the problems associated with conventional sensors. This includes dust, dirt, liquids, as well as heat and pressure effects.

Since early in 2017, Flexpoint Sensor Systems and CaptoGlove® started a strategic, collaborative relationship to deliver unique, integrated virtual reality/augmented reality (VR/AR) systems driven by Bend Sensors® to mass markets. Flexpoint continues its wide-ranging success in the Virtual Reality/Augmented Reality (VR/AR) market for Glove-Based Systems.

In June 2018, Flexpoint Sensor Systems announced two significant development opportunities. The opportunities involve the implementation of two of the Company’s Bend Sensor® technologies for vehicles, and the development of its Bend® Sensor technology and its testing and proof of concept for tracking and monitoring the use of opioids.

Last week, Flexpoint Sensor Systems announced that it continues to receive production Purchase Orders from award-winning client/partners, including South Korea-based Neofect.  This relationship, originally established in 2015/2016, brought to market smart, inventive, medical glove-based technologies, featuring the Flexpoint Bend Sensor®. Neofect produces the RAPAEL Smart Glove, which is a 2018 CES Innovation award winner.

Mr. Paul Sexauer, Flexpoint Sensor Systems’ Vice President Sales and Marketing, said, “This is the type of client relationship we look to establish, nurture and grow. We are pleased to see the success of Neofect as they have become a part of our growing client/partner base, and we’re honored to have the Bend Sensor® designed into these innovative technologies. The glove-based wearables (medical and VR/AR) market continues to be very exciting for us and one where we are clearly differentiated.”   

Flexpoint Sensor Systems, Inc. (FLXT), closed Thursday's trading session at $0.05618, down 3.87%, on 21,840 volume with 6 trades. The average volume for the last 3 months is 69,210 and the stock's 52-week low/high is $0.029/$0.09.

chart

InPlay Oil Corp. (IPOOF)

Zacks, OTC Markets, Private Capital News Wire, InvestorsHub, Stockhouse, Uptick Newswire, Penny Stock Hub, Energy Now, Dividend Investor, GuruFocus, Market Screener, Stockwatch, MarketWatch, Barchart, Wallmine, InvestorX, TradingView, The Street, Wallet Investor, and 4-Traders reported previously on InPlay Oil Corp. (IPOOF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

InPlay Oil Corp. is a growth-oriented light oil development and production company. It focuses on large oil in place pools with low recovery factors, low declines, and long life reserves mainly targeting the Cardium Formation in the Province of Alberta. The Company’s light oil focus properties provide high netbacks with fast payout on new drills. OTCQX-listed, InPlay Oil is based in Calgary, Alberta.

The Company’s Cardium assets are situated in West Central Alberta centered in the Pembina and Willesden Green pools. These pools have large oil in place reserves. In addition, there are still large reserves of unrecovered oil.

InPlay Oil’s Belly River light oil property is on the east side of the Pembina Cardium Pool. Belly River growth opportunities are concentrated around targeting oil in tight sands with low recovery factors through drilling horizontal multi-frac wells.

The Company also holds rights on a developing Duvernay light oil play. Depths are only a little more than that of the Cardium sand in Willesden Green. This results in well costs that are manageable for InPlay Oil.

Last month, InPlay Oil announced that its Board of Directors approved a $36 million Exploration and Development capital program for 2019. The approved 2019 capital program includes the completion of the two deferred horizontal wells drilled in Q4 of 2018 and also drilling roughly nine net horizontal wells with most being ERH Cardium wells in the Company’s core Willesden Green bioturbated play.

In 2018, InPlay Oil drilled 16 (11.2 net) horizontal wells in the Willesden Green area. This includes 12 (8.6 net) extended reach horizontal wells (ERH) and 4 (2.6 net) one-mile horizontal wells.

In the Duvernay, InPlay Oil completed its first horizontal well and drilled one vertical stratigraphic test well. The result is estimated annual average production of about 4,650 boe/d (70 percent oil and liquids), which attains production growth of roughly 17 percent over 2017 (22 percent for oil and liquids). This exceeds the Company’s recently increased annual production guidance of 4,600 boe/d following the two prior increases to production guidance in the second half of last year.

InPlay Oil Corp. (IPOOF), closed Thursday's trading session at $0.80795, even for the day. The average volume for the last 3 months is 15,086 and the stock's 52-week low/high is $0.6209/$1.5273.

chart

Lightwave Logic, Inc. (LWLG)

Stock Guru, OTC Picks, InvestorsHub, Silicon Investor, The Street, MarketWatch, Wallet Investor, Zacks, Standout Stocks, last10k, Barchart, FeedBlitz, HotOTC, PennyStocks24, Stockhouse, Morningstar, SmallCap Fortunes, Business Insider, and SmallCapVoice reported earlier on Lightwave Logic, Inc. (LWLG), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Lightwave Logic is a technology business centering on the development of Next Generation Photonic Devices and Non Linear Optical Polymer Materials Systems for applications in high-speed fiber-optic data communications and telecommunications. The Company creates prototype electro-optic demonstration devices. OTCQB-listed, Lightwave Logic has its corporate office in Longmont, Colorado.

The Company is moving toward commercialization of next generation photonic devices using its high-activity and high-stability organic polymers for applications in data communications and telecommunications markets. Lightwave Logic is utilizing organic nonlinear electro-optical and all-optical polymers (plastic) as the basis for a series of proprietary (internal and licensed to external partners) advanced Integrated Optical Devices, which have extensive applications in telecommunications, data communications, and optical computing for use in commercial and military markets.

Lightwave Logic has integrated its proprietary Perkinamine™ chromophore technology with other chromophores based in part on elements of proprietary, in-licensed technologies. This has resulted in a strong and durable nonlinear organic electro-optical (EO) material that will be used in photonic device development. It is founded on Lightwave Logic’s multi-chromophore approach that enables two or more chromophores to work together.


The Polymer Photonics Integrated Circuit (P2ICTM) is alike to an electronic integrated circuit. Nonetheless, it incorporates two or more optical functions or devices integrated onto a single substrate platform. The Company expects that P2ICsTM will become an important engine in the transceiver market over the next ten years. Lightwave is developing its P2IC into prototypes.

Lightwave Logic has its 50 Gbaud polymer modulator. The Company advanced from a 3 Gbps modulator to packaged 50 Gbps modulators in May of last year. In accordance with its annual plan presented at the May 2018 Annual Shareholder Meeting (ASM), Lightwave Logic continues its development of the 50 Gbaud (capable of 50 Gbps and above) packaged modulator prototypes. Furthermore, the Company has accelerated work on 100 Gbaud polymer modulators that it says are well ahead of any existing products on the market.

Lightwave Logic was granted, in December of 2018, US Patent number 10,162,111 entitled, “Multi-fiber/port hermetic capsule sealed by metallization and method”. This brings the Company’s total portfolio to 30 patents.

In January, Lightwave Logic announced that it secured a new $25 million purchase agreement with Chicago-based institutional investor Lincoln Park Capital Fund, LLC (LPC). With this agreement, and at Lightwave Logic’s sole discretion, LPC has committed to invest up to $25 million in Lightwave Logic’s common stock over a 36-month period.

Mr. Michael Lebby, Lightwave Logic’s Chief Executive Officer, said, “The new agreement will assist the Company as we continue development and commercialization of our fiber optic products aimed at high-performance and high-growth markets driven by 5G and edge data centers.”

Lightwave Logic, Inc. (LWLG), closed Thursday's trading session at $0.66, up 3.12%, on 94,897 volume with 40 trades. The average volume for the last 3 months is 96,216 and the stock's 52-week low/high is $0.63/$1.33.

chart

Pharma-Bio Serv, Inc. (PBSV)

Zacks, Market Screener, Marketbeat, Barchart, Stockopedia, Dividend Investor, Business Wire, Capital Cube, Stockhouse, Morningstar, Marketwired, Wallet Investor, last 10k, YCharts, GuruFocus, MarketWatch, and InvestorsHub reported previously on Pharma-Bio Serv, Inc. (PBSV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. The Company’s primary business is Food and Drug Administration (FDA) and other global regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico. Pharma-Bio Serv is based in Dorado, Puerto Rico. The Company also has operations in the United States, Ireland, and Spain.

Pharma-Bio Serv supports its clients through the product lifecycle. This includes research and development (R&D) Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. Additionally, this includes Quality Systems; Technology Transfer; Validation, and Manufacturing Controls & Process Support. Moreover, its services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.

Pharma-Bio Serv’s divisions include Scienza Labs, the above-mentioned PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.

Last month, Pharma-Bio Serv announced that Net Revenues from Continuing Operations for the year ended October 2018 were $17.8 million. This represents an increase of $4.5 million, or 34 percent, versus last year. Net Income for the year ended October 31, 2018 was roughly $1.3 million, an increase in Net Earnings of $2.7 million, versus the year prior.

Mr. Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, said, "Based on a corporate strategy to refocus the Company on consulting services, we sold substantially all of our laboratory business and discontinued our efforts to pursue opportunities that were not considered strategic to the Company. We believe that consulting services, which have been our core business, will provide the maximum added-value to our clients and shareholders. We are also pleased with the financial results of the Company to date and were delighted to provide a dividend to our loyal shareholders."

Pharma-Bio Serv, Inc. (PBSV), closed Thursday's trading session at $1.12, down 0.88%, on 6,410 volume with 18 trades. The average volume for the last 3 months is 4,398 and the stock's 52-week low/high is $0.432/$1.25.

chart

Processa Pharmaceuticals, Inc. (PCSA)

NetworkNewsWire, Infront Analytics, Financial Content, Stockhouse, Barchart, Dividend Investor, Stockflare, MarketWatch, Biz Journals, Marketbeat, TradingView, PR Newswire, Stockopedia, Morningstar, YCharts, InvestorsHub, Simply Wall St, last10k, Biospace, and 4-Traders reported previously on Processa Pharmaceuticals, Inc. (PCSA), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Processa Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Hanover, Maryland. It is developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions. In October of 2017, the Company acquired the assets of Promet Therapeutics, LLC. It assembled a proven regulatory science development team, management team, as well as Board of Directors. Processa Pharmaceuticals lists on the OTC Markets Group’s OTCQB.

The Processa Pharmaceuticals Team are experts in developing drug products from IND enabling studies to NDA submission. The Company’s plan is to have a pipeline of drugs that already have some proof-of-concept clinical data supporting its clinical use in the indication selected and in 2-4 years following acquisition will either have completed the pivotal study or be ready for a pivotal study and out-licensing.

Processa’s lead product is PCS-499. It will be investigated for the treatment of Necrobiosis Lipoidica, a necrotizing skin condition, caused by several pathophysiological changes. PCS-499 represents the first Processa Pharmaceuticals drug that can potentially be used in a number of unmet medical need conditions.

A second unmet medical need under investigation is the use of PCS-499 to treat radiation-related adverse effects in head & neck cancer. For both indications there is no Food and Drug Administration (FDA) approved treatments. In addition, the present standard of care is not adequate for patients.

Processa Pharmaceuticals announced in 2018 that the FDA granted the Company clearance to proceed with a Phase 2 clinical trial of PCS-499 in patients with Necrobiosis Lipoidica (NL) under an earlier submitted Investigational New Drug (IND) application. NL is a chronic, disfiguring condition affecting the skin and the tissue under the skin typically on the lower extremities with no currently approved FDA treatments. PCS-499 may provide a solution since PCS-499 and its metabolites affect numerous biological pathways, several of which contribute to the pathophysiology associated with NL.

In January, Processa Pharmaceuticals announced that the American Academy of Dermatology (AAD) selected the Processa presentation on the “Study Design and Preliminary Safety and Tolerability of PCS499 for Treatment of Necrobiosis Lipoidica (NL)” for an oral presentation and ePoster at the 2019 Annual Meeting of Washington, DC, March 1-5, 2019. Dr. Maya Das, VP of Clinical Research at Processa Pharmaceuticals will deliver the presentation.

Recently, Processa Pharmaceuticals announced the dosing of the first patient in the Phase 2 Necrobiosis Lipoidica (NL) clinical trial for PCS-499, taking place at 2 sites - University of Pennsylvania and University of Pittsburgh Medical Center (UPMC). The principal goal of the trial is to evaluate the safety and tolerability of PCS-499 in patients with NL. Nonetheless, the expectation is that the safety and efficacy data collected from the study will provide information for the design of future larger clinical trials.

Processa Pharmaceuticals, Inc. (PCSA), closed Thursday's trading session at $2.75, down 8.33%, on 3,000 volume with 2 trades. The average volume for the last 3 months is 457 and the stock's 52-week low/high is $1.50/$5.125.

chart

Torex Gold Resources, Inc. (TORXF)

Hotstocked, Penny Stock Tweets, World Trading Data, Stockhouse, Capital Cube, YCharts, Midas Letter, Marketbeat, Mining Stock Valuator, Tip Ranks, Northern Miner, InvestorsHub, Resource World, Emerging Growth, Barchart, 4-Traders, Northern Vertex, The Assay, Wallet Investor, Market Screener and Dividend Investor reported on Torex Gold Resources, Inc. (TORXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 1980, Torex Gold Resources, Inc. engages in the exploration, development, and operation of mineral properties. It explores for gold, silver, and copper deposits. An intermediate gold producer, the Company engages in the exploration, development and operation of its 100 percent owned Morelos Gold Property. This is an area of 29,000 hectares in the highly prospective Guerrero Gold Belt positioned 180 kilometers southwest of Mexico City. Torex Gold Resources has its corporate office in Toronto, Ontario.

Torex’s main assets include the El Limón Guajes Mining Complex, consisting of the El Limón, Guajes and El Limón Sur open pits, the El Limón Guajes underground mine including zones referred to as Sub-Sill, El Limón
Deep, and the processing plant and related infrastructure that began commercial production in April 2016.

The Company’s main assets also include the Media Luna Deposit, an early stage
development project, and for which Torex issued a Preliminary Economic Assessment (PEA) in 2015. This property remains 75 percent unexplored.

El Limon-Guajes is the Company’s first Mine. The El Limon-Guajes Mine (ELG), situated north of the Balsas River, constitutes one of the richest open pit gold deposits at a resource grade of 2.65 g/t. The Mine commenced gold production in December 2015. It announced commercial production on March 30, 2016. Upon being in full production, the Mine will be among the largest and lowest cost gold mines globally with expected LOM average annual production of 370,000 ounces of gold at a LOM AISC (All in Sustaining Cost) of US$616/oz.

The Media Luna deposit is hosted in a magnetic anomaly south of the Balsas River. It was discovered in March 2012. It has current Inferred Resources of 7.4 million gold equivalent ounces at a grade of 4.48 g/t.

The resource is contained in less than 30 percent of the area of the targeted magnetic anomalies. The conceptual design contained in a positive PEA (Preliminary Economic Assessment) announced in July 2015 foresees an underground operation with expected average annual production of 313,000 ounces of gold equivalent at an average AISC of US$636/oz.

Recently, Torex Gold Resources announced that during Q2 2018, a total of 80,000 ounces of gold were produced at its El Limón Guajes mine (ELG Mine) in southwest Mexico.

Torex Gold Resources also reported its financial results for the three and six months ended June 30, 2018. Gold produced in the quarter totaled 78,796 ounces in Dore, and an additional 1,300 ounces in carbon fines. Gold produced for the six months totaled 145,963 ounces in Dore, and an additional 10,187 ounces in carbon fines.

Average grade mined in the quarter was 2.45 gpt, and 2.71 gpt for the six months. Gold recovery averaged 87 percent in the quarter and 87 percent in the six months. This was consistent with design expectations.

Gold sold for the quarter totaled 77,646 ounces for total proceeds of $101.1 million at an average realized gold price of $1,302 per ounce. Gold sold for the six months ended June 30, 2018 totaled 140,552 ounces for total proceeds of $184.8 million at an average realized gold price of $1,315 per ounce.

Revenue totaled $101.8 million and Cost of Sales totaled $78.3 million, or $1,008 per ounce of gold sold for the quarter. Revenue totaled $185.8 million and Cost of Sales totaled $143.5 million, or $1,021 per ounce of gold sold for the six months ended June 30, 2018.

Torex Gold Resources, Inc. (TORXF), closed Thursday's trading session at $12.05, up 4.19%, on 52,422 volume with 125 trades. The average volume for the last 3 months is 11,196 and the stock's 52-week low/high is $5.73/$11.57.

chart

Tinka Resources Limited (TKRFF)

Hotstocked, Barchart, Stockhouse, InvestingNews, TradingView, Northern Miner, InvestorsHub, MarketWatch, Streetwise Reports, Canadian Insider, Wallet Investor, Dividend Investor, The Prospector News, 24hgold, InvestorsHangout, OTC Markets and Junior Mining Network reported on Tinka Resources Limited (TKRFF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Tinka Resources Limited is an exploration and development company headquartered in Vancouver, British Columbia. Its flagship property is the 100 percent-owned Ayawilca carbonate replacement deposit (CRD) in the zinc-lead-silver belt of central Peru (200 kilometers northeast of Lima). Tinka Resources owns 100 percent of the contiguous 150 km2 mining concessions at Ayawilca. The Company is concentrating on growing the Ayawilca Mineral Resources.

Three NI 43-101 Mineral Resources exist on the Property. The Zinc Zone and Tin Zone resources are thought to be mineable by underground methods for resource calculation purposes. The Colquipucro Silver Zone is thought to be mineable by open pit methods.

The Ayawilca Zinc Zone Inferred Mineral Resource estimate currently comprises 42.7 Mt at 6.0 % zinc, 0.2 % lead, 17 g/t silver, and 79 g/t indium. It also consists of a Tin Zone Inferred Mineral Resource of 10.5 Mt at 0.63 % tin, 0.23 % copper & 12 g/t silver.

Recently, Tinka Resources announced assay results for eight step-out drill holes from the West, Central, Camp and East Ayawilca areas in the Company's continuing resource drill program at the Ayawilca project, Peru. Furthermore, one infill hole at South Ayawilca is reported.

Highlights include two high-grade zinc intersections at the newly named Camp area (holes A18-130 & 134) in the 'gap' between West and Central Ayawilca including 5.7 meters grading 14.9% zinc. The intercept occurs within a repeated limestone unit underneath phyllite.

At West Ayawilca, two follow-up holes to hole A18-129 (10.4 meters at 44.0% zinc) have also intersected high-grade zinc mineralization beneath the known zinc resource. Zinc-rich veins hosted by phyllite in hole A18-132 (including 6.9 meters grading 20% zinc) are believed to be feeder structures that have tapped the source for the zinc mineralization and provide further potential for more mineralization at depth.

Moreover, a positive infill hole at South Ayawilca (A18-133) confirms high-grade zinc replacement mineralization hosted by limestone and sandstone. The hole has improved the geological model in that region.

Tinka Resources Limited (TKRFF), closed Thursday's trading session at $0.23, down 2.07%, on 36,250 volume with 8 trades. The average volume for the last 3 months is 43,286 and the stock's 52-week low/high is $0.207/$0.478.

chart

Novo Integrated Sciences, Inc. (NVOS)

OTC Markets, Simply Wall St, Stock Orange, InvestorPlace InvestorsHub, Corporateinformation, TradingView, Stockhouse, MarketWatch, and Investing News Alerts reported on Novo Integrated Sciences, Inc. (NVOS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Novo Integrated Sciences, Inc. is a provider of multi-disciplinary primary healthcare services and products in Canada via its wholly-owned Canadian subsidiary Novo Healthnet Limited (NHL). The Company’s mission is to build a U.S. and Canadian based multi-disciplinary primary healthcare service provider that provides first-class specialized healthcare services and products through the integration of technology and medical science.

Novo Integrated Sciences is headquartered in Bellevue, Washington. The Company lists on the OTCQB.

Novo Healthnet Limited (NHL) - directly and indirectly, by way of its contractual relationships - provides its specialized services to more than 300,000 patients each year. The Novo Family's services include pain assessment, treatment, management, and prevention. These are provided in corporate owned clinics, homes, and institutional locations throughout Canada.

NHL owns a 100 percent stake in Novo Assessments, Inc., Novo Healthnet Rehab Limited, Novo Peak Health, Inc., and an 80 percent stake in Novo Healthnet Kemptville Centre, Inc., all of which are Province of Ontario companies.

The Novo Family provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, and massage therapy. Moreover, it provides acupuncture, chiropodist, neurological functions, kinesiology, certain dental assessments, certain long-term care services, and other para-medical services to its clients.

In December 2017, Novo Integrated Sciences announced that it completed the purchase of certain assets of Executive Fitness Leaders (EFL). EFL is an Ottawa, Ontario based local leader in the private personal training sector. EFL provides personal training, massage therapy, nutritional counseling, as well as corporate wellness services.

Novo Integrated Sciences, through its wholly-owned U.S. based subsidiary, Novomerica Health Group, Inc., a Nevada corporation, announced in March of this year a signed Letter of Intent (LOI) to acquire Illinois Spine and Disc Institute, Ltd. (ISDI) and Progressive Health and Rehabilitation, Ltd. Both of these entities are Illinois based medical care corporations commited to the diagnosis, treatment and rehabilitation of peripheral neuropathy related spine and neck disorder.

Novo Integrated Sciences’ multi-disciplinary primary healthcare services and protocols are directed at assessment, treatment, management, rehabilitation and prevention via its 14 corporate owned clinics, 86 affiliate clinics, 9 retirement homes and more than130 long-term care facilities across Canada.

Novo Integrated Sciences, Inc. (NVOS), closed Thursday's trading session at $1.6575, up 7.39%, on 742 volume with 5 trades. The average volume for the last 3 months is 6,068 and the stock's 52-week low/high is $0.1135/$2.99.

chart

Rennova Health, Inc. (RNVA)

Barchart, Preferred Stock Channel, Street Insider, StockTwits, InvestorsHub, and Stockhouse reported on Rennova Health, Inc. (RNVA), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Rennova Health, Inc. is a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers. The Company opened its first rural hospital in Oneida, Tennessee on August 8, 2017. Rennova Health delivers an efficient, effective patient experience and first-rate clinical outcomes. The Company is based in West Palm Beach, Florida. Rennova Health has its Medytox Diagnostics subsidiary.

Essentially, Rennova Health is a single-source healthcare solutions company. It centers on serving essential healthcare categories, particularly those with unmet needs and major opportunities for innovation-driven solutions. The Company develops and operates progressive businesses, systems and services to support better treatment outcomes, more cost-effective patient care, and optimized revenue streams.

Rennova Health’s solutions include industry-leading diagnostic laboratory testing and analytics for precision medicine, and specialized and streamlined EHRs and other essential software services. Its solutions also include complete medical billing and financial services for enhanced revenue cycle management.

The Big South Fork Medical Center opened under Rennova Health’s ownership with services that include a 24/7 emergency department along with radiology services that include X-ray, CT scan and ultrasound. Furthermore, other available services include a laboratory, respiratory therapy, physical therapy, a medical/surgical unit, and swing beds.

Rennova’s Medytox Diagnostics subsidiary owns and operates five high-complexity CLIA-certified labs strategically located across the nation. These labs specialize in urine drug testing for prescription medications, drugs of abuse and complete pain medication testing.

The labs also provide testing services in the areas of clinical chemistry, toxicology, hematology, immunology, serology, bacteriology and esoteric testing services, including neurotransmitter testing, with a wide array of sampling options that include the Company’s proprietary methodology.

Rennova Health also has its comprehensive medical billing services company, Medical Billing Choices (MBC). MBC operates as the in-house billing company for all Rennova Health businesses and labs.

Recently, Rennova Health announced that its flagship Laboratory, EPIC Reference Labs, Inc. (EPIC), successfully met the Laboratory Accreditation Program Standards for Accreditation from the College of American Pathologists (CAP). Since 2015, EPIC has been operating as a urine toxicology testing laboratory in Riviera Beach, Florida.

Under the CAP Accreditation, EPIC Reference Labs has been accredited for the All Common, Chemistry, Director/Organizational Assessment, Hematology, Immunology, Laboratory Central, Special Chemistry, Toxicology and Urinalysis testing services. In addition, subspecialty accreditation was granted for Endocrinology, General Immunology, Hematology, Routine Chemistry, Toxicology, Urinalysis and Syphilis Serology.

At the end of January, Rennova Health announced that it entered into a definitive asset purchase agreement to acquire an acute care hospital in Jamestown, Tennessee. The hospital, known as Tennova Healthcare - Jamestown, and its associated assets are being acquired from Community Health Systems, Inc. (CYH).

Tennova Healthcare - Jamestown is a fully operational 85-bed facility.  The expectation is that this transaction will close in Q2 of 2018, subject to customary regulatory approvals and closing conditions.

Currently, Rennova Health operates in three synergistic divisions. One is clinical diagnostics via its clinical laboratories. The second is supportive software solutions to healthcare providers. This includes electronic health records (EHR), laboratory information systems (LIS) and medical billing services. The third is the recent addition of the hospital in Tennessee.

Rennova Health, Inc. (RNVA), closed Thursday's trading session at $0.0002, up 100.00%, on 746,403,675 volume with 298 trades. The average volume for the last 3 months is 27,719,649 and the stock's 52-week low/high is $0.00009/$17.00.

chart

HedgePath Pharmaceuticals, Inc. (HPPI)

BUYINS.NET, MarketWatch, InvestorsHub, and Stockhouse reported earlier on HedgePath Pharmaceuticals, Inc. (HPPI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It discovers, develops, and plans to commercialize leading-edge therapeutics for patients with cancer. The Company is looking to repurpose the Food and Drug Administration (FDA) approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HedgePath Pharmaceuticals is headquartered in Tampa, Florida.

HedgePath is the exclusive U.S. licensee of a patented formulation of itraconazole, named SUBA-Itraconazole. Clinical studies have shown it to have more bioavailability than generic itraconazole. The Hedgehog signaling pathway is a significant regulator of cellular processes in vertebrates. This includes cell differentiation, tissue polarity, as well as cell proliferation.

HedgePath Pharmaceuticals believes (based on published research) that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Leveraging research undertaken by key investigators in the field, the Company’s plan is to explore the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization.

The design of “SUBA technology” (which stands for “super bioavailability”) is to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole is a patented formulation developed by Mayne Pharma. It has improved absorption and substantially reduced variability in comparison to generic itraconazole.

In July of 2017, HedgePath Pharmaceuticals announced that the FDA provided further guidance concerning the Company’s continuing, open-label Phase 2(b) clinical trial studying the effect of SUBA-Itraconazole (SUBA-Cap) oral capsules in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. BCCNS results from a genetic mutation that causes the Hedgehog pathway (a major regulator of processes in cells) to function improperly, leading to the chronic formation of basal cell tumors.

The FDA's guidance came in the form of a written response by the FDA to HedgePath Pharmaceuticals’ Type-C meeting background package.  Such a meeting is a standard element of the regulatory review process leading to a potential New Drug Application (NDA) to the FDA.

Recently, HedgePath Pharmaceuticals announced that it completed enrolment in its earlier announced open label, Phase 2(b) SCORING clinical trial, testing SUBA™-Itraconazole in patients with BCCNS (Basal Cell Carcinoma Nevus Syndrome - or Gorlin Syndrome).

HedgePath Pharmaceuticals also announced that it entered into a definitive preferred stock and warrant Securities Purchase Agreement with its majority stockholder Mayne Pharma.

Mayne Pharma agreed to invest up to $5 million in HedgePath Pharmaceuticals, the first $2.4 million of which was received by the Company on January 10, 2018, with a second tranche of $1.6 million to be funded by mid-2018, and a third tranche to be funded by year end if HedgePath Pharmaceuticals’ pending New Drug Application (NDA) for the SUBA-Itraconazole treatment of Basal Cell Carcinoma Nevus Syndrome (BCCNS) is accepted for filing by the FDA.

HedgePath Pharmaceuticals, Inc. (HPPI), closed Thursday's trading session at $0.1199, up 19.90%, on 1,700 volume with 2 trades. The average volume for the last 3 months is 15,216 and the stock's 52-week low/high is $0.0402/$0.375.

chart

Sun BioPharma, Inc. (SNBP)

AheadoftheBulls.com, AllPennyStocks, TheStockWizards.net, The Dean, FeedBlitz, MicrocapVoice, Today's Financial News, HotPennyStocksNow, OTC Picks, Hot Shot Stocks, Wall Street Resources, Beacon Equity Research, Greenbackers, CoolPennyStocks, Otcstockexchange, HotOTC, and Lebed.biz reported previously on Sun BioPharma, Inc. (SNBP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Sun BioPharma, Inc. is a biopharmaceutical company listed on the OTC Markets Group’s OTCQB. The Company is developing disruptive therapeutics for the treatment of patients with pancreatic diseases. A clinical-stage biopharmaceutical company, Sun BioPharma’s development programs target diseases of the pancreas. This includes pancreatic cancer and pancreatitis. Sun BioPharma has its corporate headquarters in Waconia, Minnesota.

The Company’s initial product candidate is SBP-101. This product is for the treatment of patients with pancreatic cancer. Mr. Ray Bergeron, Ph.D. Distinguished Professor Emeritus, University of Florida invented SBP-101. Sun BioPharma’s plan is to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, which is the most common kind of pancreatic cancer.

SBP-101 is a first-in-class, proprietary, polyamine compound. The design of it is to exert therapeutic effects in a mechanism specific to the pancreas. The Company originally licensed SBP-101 from the University of Florida in 2011.

The molecule has been demonstrated to be highly effective in human pancreatic cancer models. It has shown superior activity to existing Food and Drug Administration (FDA) approved chemotherapy agents. Additionally, combination therapy potential has been demonstrated for pancreatic cancer.

In addition, Sun BioPharma’s SBP-102 is presently in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. As well, Sun BioPharma’s SBP-103 is currently in non-clinical exploratory evaluation.

Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, California; the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia, and the Ashford Cancer Centre in Adelaide, Australia.

Sun BioPharma announced in October 2017 the successful completion of patient enrolment in its Phase 1a dose escalation safety study using SBP-101 for patients with previously treated locally advanced or metastatic pancreatic ductal adenocarcinoma (PDA). Upon reviewing data from the sixth and final cohort of patients, and data from all 29 patients enrolled in the study, the Data Safety Monitoring Board (DSMB) recommended a safe and well-tolerated dose level of SBP-101 to be used for more clinical development.

Recently, Sun BioPharma announced its initiation of a first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer. The anticipation is that the first patient will be enrolled in early Q2 2018.

The expectation is that clinical sites participating in the study will include the University of Florida, in Gainesville, Florida, the Ashford Cancer Centre in Adelaide, the Olivia Newton-John Cancer and Wellness Centre in Melbourne and the Blacktown Cancer and Haematology Centre in Sydney, Australia.

Furthermore, Sun BioPharma announced the completion of the first-in-human safety study of SBP-101 in previously treated patients with pancreatic ductal adenocarcinoma (PDA). SBP-101 was well tolerated. Moreover, signals of efficacy were observed at dose levels below the Maximum Tolerated Dose (MTD).

Sun BioPharma, Inc. (SNBP), closed Thursday's trading session at $3.25, up 1.56%, on 250 volume with 1 trade. The average volume for the last 3 months is 215 and the stock's 52-week low/high is $2.05/$15.00.

chart

Abtech Holdings, Inc. (ABHD)

Greenbackers, Stealth Stocks, Wyatt Investment Research, Investor Ideas, Stock Mister, OTC Journal, The Stock Psycho, Wall Street Resources, FeedBlitz, Topgun stockpicks, Hidden Values Alert, CoolPennyStocks, and AllPennyStocks reported earlier on Abtech Holdings, Inc. (ABHD), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Abtech Holdings, Inc. is a full-service environmental technologies and engineering company. It provides creative solutions to communities, industry, as well as governments addressing issues of water pollution and contamination. Abtech provides solutions for Stormwater Management, Oil & Gas Water Treatment, and Industrial Water Treatment. OTCQB-listed, Abtech Holdings is based in Scottsdale, Arizona. AbTech Industries, Inc. is a subsidiary of Abtech Holdings.

Abtech began marketing of produced water and industrial wastewater treatment, and established its engineering subsidiary AEWS Engineering in 2012. AEWS is an independent civil and environmental engineering firm partnered with foremost research and engineering universities.

The foundation of Abtech’s products is on polymer technologies, which can remove hydrocarbons, sediment, and other foreign elements in stormwater runoff, flowing water, and industrial process and wastewater. Abtech’s products include advanced filtration media technologies and different water treatment systems.

The Company’s offerings include the antimicrobial technology- Smart Sponge® Plus. This technology is effective in reducing coliform bacteria found in stormwater, industrial wastewater, and municipal wastewater. Smart Sponge® Plus is registered with the Environmental Protection Agency (EPA).

Abtech has installed and validated onsite its first mobile water pre-treatment system centered on oil recovery and hydrocarbon removal for the treatment of flowback and produced water for the on-shore Oil & Gas industry. This pre-treatment system integrates its Smart Sponge® technology. The design of it is to operate in advance of other treatment systems, boosting overall efficiency and lessening treatment cost.

Abtech Holdings continued its activity in 2017 with several water treatment field trials. It prepared for the second field test of evaporative technology for produced and frac flowback water with a concentration on emissions. It successfully completed a Smart Sponge® hydrocarbon removal and recycling of spent media demonstration in a produced water application for its Colombian distributor, advancing discussions to economics and design issues. In addition, it achieved low phosphorus results on a sanitary wastewater application in China.

Recently, Abtech Holdings announced that it and United Stormwater, Inc. collaborated to bring two best-in-class technologies together, providing an inventive solution for developing stormwater challenges in southern California. A municipality in Los Angeles County, California retrofitted existing infrastructure using United Stormwater's Wing-Gate™ Screens, auto-retractable curb inlet screen covers, and Abtech's Ultra-Urban® Filters, catch basin inserts, so as to prevent stormwater contamination that flows into Legg Lake, one of Los Angeles County's biggest and most popular recreation areas. United Stormwater is a full service stormwater management company.

Abtech Holdings, Inc. (ABHD), closed Thursday's trading session at $1.04, up 0.97%, on 132 volume with 4 trades. The average volume for the last 3 months is 576 and the stock's 52-week low/high is $0.51/$3.58.

chart

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE:PLUS) (OTCQB:PLPRF) (the “Company” or “PLUS”) is pleased to announce that co-founders, Jake Heimark and Justin ‘Crunchy’ Gwin are featured on Business TV (B-TV), a half-hour weekly investment show profiling emerging market leaders. In the recorded interview Heimark and Gwin provide an insightful perspective on how the company earned recognition as the leading cannabis edibles company in California.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $5.55476, up 4.81%, on 30,048 volume with 110 trades. The average volume for the last 3 months is 113,104 and the stock's 52-week low/high is $2.81/$6.01.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands, Inc. (CSE: GGB) (OTCQB: GGBXF) (GGB or the Company) is pleased to announce the opening of two new Seventh Sense CBD shops, located in Glenbrook Square, Fort Wayne, Indiana and in Hamilton Place, Chattanooga, Tennessee. These new shops represent the next step in Green Growth Brands' plan to dominate CBD retailing and planned network of hundreds of shops designed to serve customers across the United States. Also today, the company was highlighted in an article explaining how Cannabis beauty and wellness products have gone mainstream.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $3.925, off by 0.43%, on 253,884 volume with 436 trades. The average volume for the last 3 months is 196,461 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries. The Company today announced that analytical testing on hemp-derived CBD oil processed via PBI's Ultra Shear Technology™ (UST™) platform has confirmed that UST processing uniquely achieves the challenging criteria for creating highly-effective "nanoemulsions" of CBD oil in water, without loss or modification of CBD throughout the entire UST process (> 99% recovery).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.55, up 4.72%, on 24,607 volume with 80 trades. The average volume for the last 3 months is 12,810 and the stock's 52-week low/high is $1.52/$4.99.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was highlighted today in a publication from Financialnewsmedia.com, examining how U.S. and Canadian cannabis companies, witnessing the CBD-rush, have started developing their own strategies to tap the plant’s potential. Just recently, Canopy Growth Corp. announced it would spend $150 million to set up a hemp facility in New York state, where hemp-derived CBD would be extracted and sold to consumers there.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.767, up 0.54%, on 347,274 volume with 224 trades. The average volume for the last 3 months is 377,122 and the stock's 52-week low/high is $0.413/$1.995.

Recent News

chart

Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Green Hygienics Holdings (OTCQB: GRYN), a full-scope, premium cannabis company, holds an advantageous position to capitalize on the growing global demand for medical and recreational cannabis. To view the full article, visit: http://nnw.fm/q9Evz.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $0.58, up 9.85%, on 78,602 volume with 50 trades. The average volume for the last 3 months is 20,976 and the stock's 52-week low/high is $0.05/$0.579.

Recent News

chart

Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF)

The QualityStocks Daily Newsletter would like to spotlight Phivida Holdings Inc. (PHVAF).

Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF) was highlighted today in a publication examining how, with the global CBD movement supercharged by the 2018 U.S. Farm Bill, cannabis and beverage companies alike are officially beginning to launch CBD-infused beverage products in the U.S. market. The rollout of various CBD-infused beverages throughout Q1 and Q2 2019 in the United States will likely set the foundation for hemp infused markets across the world, as these brands will gain a first-mover advantage in the emerging subsegment of what could become the world’s largest functional drinks market.

Headquartered in Vancouver, Canada, with operations in San Diego, Calif., Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF)  is a premium food and beverage company that focuses on whole plant nutrition and natural ingredients that help best maintain overall health and balance in the human body. The company infuses active hemp into a variety of premium foods, beverages and supplements and is poised for global distribution. Phivida is guided by a team of Fortune 500-caliber executives focused on a new strategic portfolio of products and brands, comprehensive consumer research, new product and brand development, improved visual identity and packaging design, and a strong distribution strategy.

The company’s mission is to become a leader in whole plant solutions by providing holistic remedies for a more natural alternative to pharmaceuticals and by guiding people toward a healthy lifestyle. Phivida embraces and celebrates a return to organic, natural, plant-based foods and beverages and a focus on holistic health and wellness.

Publicly traded on the Canadian Securities Exchange (CSE: VIDA) and the OTCQX Best Market in the U.S. (OTC: PHVAF), the company’s strong balance sheet carries CAD$13 million with no debt or loans with ~60 million shares outstanding, and the company is now well-capitalized to fund major mainstream distribution with a solid structure that is poised for long-term growth.

Management

Phivida’s management team includes president and CEO Jim Bailey, former president of Red Bull Canada and global chief marketing officer for Merrell Outdoors; Chief Marketing Officer Michael Cornwell, former chief marketing officer for Samsung New Zealand and the former director of marketing for Red Bull Canada; and Doug Campbell, former director of sales for Red Bull North America, who, as Phivida’s chief commercial officer, is tasked with driving new sales revenue growth.

The Science

Using encapsulation technology, Phivida uses full spectrum CBD-hemp oil (rich in naturally occurring phytocannabinoids) converted into a water-soluble delivery format, which enhances delivery and absorption of the cannabinoids into the human body – up to an estimated tenfold.

The whole plant hemp extract is infused into functional beverages, food and supplements to target a range of health and wellness conditions. Phivida strives to lead the industry in product quality through high-quality ingredients and best-in-class testing. The Company has partnered with Flora Labs to test and ensure consistency and potency of all products. Flora Labs is a world-class testing lab with stringent QA and QC quality assessment protocols and will provide Phivida with ongoing impartial quality testing.

Regulations

Federally legal under the 2014 Farm Bill, CBD from hemp oil is a rapid growth market across the U.S. When derived from marijuana, CBD remains a schedule 1 controlled substance, giving hemp-derived CBD oil-infused products a competitive advantage on regulations. On June 28, 2018, the U.S. Senate passed the Agriculture Improvement Act of 2018 (i.e. the “Farm Bill), lifting the U.S. Industrial Hemp laws to an agricultural commodity status and effectively removing hemp from the controlled substance list.

Earlier this year, another milestone court ruling also provided significant regulatory support for the U.S. CBD-hemp sector. In February 2018, the Supreme Court presided over the HIA (Hemp Industry Association) vs. DEA (Drug Enforcement Agency) in a class-action suit concerning the issue of CBD extracted from hemp and the legality of industrial hemp. In the final ruling, the Supreme Court unequivocally determined that hemp (and its derivatives), when produced domestically under the Farm Bill, are not a controlled substance.

The Supreme Court ruling also found the Farm Bill (as it relates to hemp) “pre-empts” the Controlled Substances Act. Congress has since exempted Farm Bill hemp from the Controlled Substances Act (CSA), giving the Farm Bill primary jurisdiction over the governance of the CBD-hemp oil industry in the U.S.

The DEA further conceded it does not “seek to control cannabinoids” and that only marijuana-derived cannabinoids are governed under the Controlled Substances Act. In May of 2018, the DEA issued a formal directive to all federal agencies (e.g., U.S. Customs and Border Patrol) stating that cannabinoids are not controlled substances unless derived from marijuana, and that the “mere presence of cannabinoids” in any product or derivative does not render it a controlled substance. The Supreme Court ruling also resulted in the mediation of a settlement in what is now the third successful HIA vs. DEA suit in over a decade.

In Canada, the Senate approval of Bill C-45 legalized the production, distribution and use of recreational cannabis, with edibles to be added in 2019. The bill officially became law as of Oct. 17, 2018, creating a legal framework for the production, distribution, sale and possession of cannabis across Canada including cannabinoid-infused beverages.

Phivida Brands

  • Vida+: Vida+ is the company’s premium, clinical-grade-strength, full-spectrum hemp oil extract and capsule line designed to help people feel their best. The products are sourced from the best organic hemp and natural ingredients on the market and are third-party lab tested for quality, purity and potency at world-class facilities.
  • Oki: The Oki lifestyle brand is the company’s newly launched line of functional beverages and supplements infused with active hemp extract and will be available to consumers in up to 2,400 natural specialty store locations within the United States. Oki beverages are infused with 10 milligrams of active hemp extract per bottle and come in two different formulations: iced teas and flavor-infused water, each available in four different 16-ounce flavors. Oki supplements are available in tinctures or capsules that range in doses from 600-1,800 total milligrams of active hemp extract.
  • All products contain non-GMO, natural and organic ingredients and are plant-based and vegan friendly and packaged in sleek, 100 percent recyclable glass containers.

WeedMD-Phivida Joint Venture

Phivida has partnered with WeedMD Inc. (TSX-V: WMD) (OTC:WDDMF) (FSE:4WE), a Health Canada federally licensed producer and distributor of medical cannabis, to form a joint venture focused on manufacturing, marketing and distributing cannabinoid-infused beverages. CanBev is on track to build and operate the first cannabis-infused beverage production facilities in Canada. The joint venture will focus on manufacturing, marketing and distributing cannabinoid-infused beverages for the legalized medical and adult-use cannabis markets. WeedMD will be the exclusive cannabis supplier and distributor for CanBev cannabis-infused beverages. Phivida will be responsible for product innovation, research and development, formulation and branding.

Strategic Agreements

Phivida has an exclusive national agreement with Natural Specialty Sales (“NSS”), an Acosta company. NSS is recognized as the industry leader in natural/specialty retail channel trade across the U.S. Phivida’s launched OKI brand of premium CBD products is now the exclusive CBD-infused beverage and health supplements products brand represented by NSS. This establishes Phivida as the first CBD brand company to officially cross over into national mainstream distribution across the U.S., providing new access to over 2,400 retail locations in a major distribution channel market valued at over USD $4.1 billion in retail sales.

The NSS exclusive agreement provides access to a national network of retail stores across the U.S. This national network includes major retail banners such as: Whole Foods Market, Sprouts Farmers Market, National Coop Grocers, etc. The partnership also provides the opportunity to access an additional 25,000 national conventional grocery supermarkets, including Walmart, Target, Kroger, Publix and others, via Acosta’s national sales network.

Further Information

www.Phivida.com
+1 (844) 744-6646 (ext. #2)
IR@Phivida.com

Phivida Holdings Inc. (PHVAF), closed the day's trading session at $0.41, up 17.14%, on 133,127 volume with 51 trades. The average volume for the last 3 months is 33,472 and the stock's 52-week low/high is $0.05/$1.80.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G) expanded its leadership team recently to strengthen its leading position as a cannabis beverage formulation company. To view the full article, visit: http://nnw.fm/4RAIv.

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed the day's trading session at $0.301, up 2.03%, on 176,541 volume with 67 trades. The average volume for the last 3 months is 272,255 and the stock's 52-week low/high is $0.189/$1.875.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions, Inc. (OTC: SGSI) (“Spectrum Global” or the “Company”), a single-source provider of end-to-end next-generation wireless and wireline network solutions and professional services to the service provider (carrier) and corporate enterprise markets, today announces that year-to-date it has received over $5.8 million in new contract awards to support carrier network upgrades. Also today, the company was featured in an article discussing SGSI’s recently announced that an equity investment by WaveTech Global has allowed the company to reduce an outstanding debt incurred through a previous acquisition (http://nnw.fm/jFA3M).

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.139, up 26.36%, on 203,994 volume with 38 trades. The average volume for the last 3 months is 39,744 and the stock's 52-week low/high is $0.0813/$2.59.

Recent News

chart

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

Redfund Capital (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) today announced an expansion of its current advisory agreement with Wahupta Ventures Inc. to include new financing. To view the full press release, visit: http://nnw.fm/P6nqI.

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

  • Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
  • Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

  • Diversifying investments in Canada and other countries
  • Building an international footprint with established national leaders
  • Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
  • Introducing companies to Canada as a viable option for public listings
  • Becoming a premier go-to lender for established companies

The company’s revenue sources include:

  • Interest-bearing debt instruments with asset-backed collateral to securitize loans
  • Equity kicker of warrants coverage on original loan
  • Conversion ability of loan in its entirety
  • Advisory fees from contracts for consulting on growth strategies
  • Right of first refusal on future financing in each company funded

Redfund Capital Corp. (PNNRF), closed the day's trading session at $0.1873, even for the day. The average volume for the last 3 months is 207 and the stock's 52-week low/high is $0.10/$0.505.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study that evaluated TurboCBD™, the Company's proprietary, DehydraTECH™ powered, cannabidiol (''CBD'') fortified hemp-oil capsule.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.3595, off by 8.14%, on 109,684 volume with 145 trades. The average volume for the last 3 months is 189,240 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, is pleased to share that Earth Science Foundation, Inc. (“Foundation”), the creation of which it has supported, is now a 501(c)(3) organization. Obtaining non-profit status enables the Foundation to accept tax-free contributions that will fund further studies of cannabidiol (“CBD”) products with a primary object of helping those who suffer from cancer, epilepsy, depression, autism, chronic pain, dementia, drug/alcohol addiction, and AIDS.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.673, off by 3.86%, on 33,928 volume with 32 trades. The average volume for the last 3 months is 33,632 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals Corp. (TSXV: QMC) (FSE: 3LQ) (OTC Pink: QMCQF) ("QMC" or "the Company") is pleased to announce that drilling has commenced on its Irgon Lithium Mine Project located within the prolific Cat Lake-Winnipeg River rare-element pegmatite field of S.E. Manitoba, which also hosts the nearby Tantalum Mining Corporation of Canada ("TANCO") rare-element pegmatite. Also today, NetworkNewsWire released a report on the company detailing how demand for lithium from battery makers is anticipated to nearly double in the years up to 2027 and the automobile industry is expected to play a huge role in driving demand, as the world makes an increasingly pronounced shift toward electric vehicles.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.23258, up 6.06%, on 40,840 volume with 20 trades. The average volume for the last 3 months is 61,967 and the stock's 52-week low/high is $0.1155/$0.726.

Recent News

chart

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Vertically integrated North American pure-play cobalt company First Cobalt (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) this morning announced the appointment of former Governor C.L. "Butch" Otter to its board of directors. To view the full press release, visit: http://nnw.fm/MT0xc.

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.134428, off by 2.52%, on 56,893 volume with 33 trades. The average volume for the last 3 months is 150,438 and the stock's 52-week low/high is $0.108/$0.978.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint Inc. (OTCQB: SING), a client of CNW with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. To view the full publication, titled “More Mergers Expected as Cannabis Sector Heads into New Year of Growth,” visit: http://cnw.fm/Racz8.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.0188, off by 0.53%, on 3,131,582 volume with 143 trades. The average volume for the last 3 months is 5,959,488 and the stock's 52-week low/high is $0.0106/$0.0753.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.